Markets Don't Just Price Risk—They Price Waiting

What return do investors require to finance years of pre-revenue uncertainty? Traditional valuation frameworks offer limited guidance for answering this question in early-stage companies, where the dominant risks are often idiosyncratic and poorly captured by conventional measures such as beta.

In our previous article, What the Market Knows That WACC Doesn’t – CFA Institute Enterprising Investor, we introduced the MIDR — the discount rate that equates expected future cash flows, based on consensus forecasts, to the current stock price. Unlike the weighted average cost of capital (WACC), market-implied discount rate (MIDR) reflects the return investors are implicitly demanding, incorporating their assessment of risk, credibility, and future performance.

By examining MIDRs across a sample of publicly listed life sciences companies, we find that the market's required return is closely linked to the timing of key milestones -- particularly commercialization and initial profitability. Put simply, investors appear to demand compensation not only for uncertainty, but also for how long they must wait before uncertainty begins to resolve.

This insight is especially relevant for early-stage companies. Capital asset pricing model (CAPM)-based discount rates often struggle to capture the clinical, regulatory, and commercialization risks that dominate outcomes at this stage. As a result, investors and entrepreneurs often rely on broad rules of thumb or dated studies of venture capital returns. (See Plummer1, Scherlis and Sahlman2, and Sahlman and others3). An MIDR analysis of publicly listed life sciences companies offers a market-based alternative and sheds new light on how investors price timing risk.

By combining advanced automation with sell-side analyst estimates, we derive bespoke cash flow models for any early-stage public company with sufficient analyst coverage. We leverage analyst estimates for revenue, profitability, and investment over the period considered dependable (typically 7–10 years) and extend them using an H‑model to a long-term steady state4. We solve for the MIDR that equates expected future cash flows to the market value of invested capital.

Using S&P Capital IQ data, we identified 32 publicly traded life sciences companies with the requisite criteria and data availability to observe their MIDRs and shed light on the required returns for early-stage life sciences companies. While the screen targets “early-stage” companies, our sample includes firms spanning clinical through early commercial stages.

The criteria include:

• Market capitalization greater than $1 billion
• Pre-revenue and loss-making
• Sufficient equity analyst coverage (e.g., three or more analysts)
• Sufficient years of consensus estimates to capture mature state of revenue growth and profitability
• Domiciled in the US to eliminate differences in financial reporting

As shown below, the MIDRs for our population have a wide range, 15% at the low end to 39% at the high end. However, examining the interquartile range, we observed a range of 20% to 27% and an average and median of 24%.

These observations are broadly consistent with prior studies reporting required returns between 20% and 35%. However, unlike these studies, we examine the fundamental drivers of returns.

We examined the relationship between the observed MIDR for each company, and three primary elements of unsystematic risk:

• Time to market (commercialization): measured as the first year in which material revenue is forecasted by analysts
• Time to initial profitability: measured as the first year in which the company is forecasted by analysts to have a positive operating profit
• Time to market maturity: measured as the year in which analyst estimates for growth and operating profit begin to normalize to long-term expectations

We find that MIDR increases systematically with the timing of key cash flow gates. The strongest relationship is time to commercialization (first year of material revenue). Time to initial profitability is also positively related to MIDR, but with smaller magnitude. By contrast, the timing of “normalized” profitability (a proxy for maturity) is not statistically significant in this sample once earlier milestones are considered. Collectively, the results suggest that the duration of pre-revenue uncertainty is a primary driver of the market's required return.

Consistent with our hypothesis, the further into the future commercialization is expected, the higher the implied return required by investors. A simple regression implies roughly +2.8% MIDR per year of delayed commercialization in this sample. MIDR also rises as the expected year of initial operating profit moves out further into the future. A simple regression implies roughly +2.1% MIDR per year of delayed profitability.

Finally, markets appear to treat steady-state maturity as a refinement rather than the core risk driver, especially when earlier milestones already convey most of the schedule risk.

Bringing the pieces together, we derive the matrix below to estimate the MIDR for various combinations of time to commercialization and time to profitability.

While this grid should be calibrated to company-specific facts, it provides an empirically grounded starting point for required‑return selection where traditional WACC offers limited insight.

MIDR has practical applications across valuation, value creation, and capital allocation for early-stage companies.

First, MIDR provides an empirically grounded framework for selecting discount rates in notoriously difficult-to-value early-stage businesses. The observed relationships between required returns, time to commercialization, and time to profitability allow analysts to calibrate discount rates to a company's specific development and commercialization timeline.

Second, because timing is a key driver of MIDR, it becomes an actionable lever for value creation. Management teams can potentially reduce implied risk premia by accelerating critical milestones and increasing confidence in execution.

Finally, MIDR can improve both capital allocation and capital raising decisions. Aligning hurdle rates with market-implied returns creates a more market-aware approach to investment decisions, while providing entrepreneurs and investors with a practical benchmark for assessing enterprise value and the cost of capital.

MIDR provides a practical, market-based framework for estimating required returns in early-stage life sciences companies, where traditional CAPM/WACC approaches often fail to capture the dominant sources of risk. Our findings suggest that investors primarily demand compensation for the duration of pre-revenue uncertainty, with the timing of commercialization and profitability serving as key drivers of required returns.

By revealing how markets price development timelines, MIDR provides a common framework for valuation, capital allocation, and strategic decision-making. It transforms the discount rate from a static assumption into a market-informed measure that connects strategy, execution, and valuation.

The views reflected in this article are the views of the author(s) and do not necessarily reflect the views of Ernst & Young LLP or other members of the global EY organization.